Home Journals Articles Updates About
CN
image
收藏切换
Analysis of pre-marketing and post-marketing clinical pharmacology studies in conditional approvals for oncology drugs in China and the United States
收藏切换
PDF
Jing AN1, Cheng-hao GE2, Yang LIU2, 3, Sen LIU3, Chen YIN3, Yi LI4, Jing-can WANG5, Xiao-yuan CHEN2, 3
Chinese Journal of Clinical Pharmacology | 2026, 42(11) : 1631 - 1639
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(11): 1631-1639
• Drug Evaluation and Administration •
Analysis of pre-marketing and post-marketing clinical pharmacology studies in conditional approvals for oncology drugs in China and the United States
Full
Jing AN1, Cheng-hao GE2, Yang LIU2, 3, Sen LIU3, Chen YIN3, Yi LI4, Jing-can WANG5, Xiao-yuan CHEN2, 3
Affiliations
  • 1.R&G PharmaStudies Co., Ltd, Beijing 100048, China
  • 2.Clinical Trial Center for Drugs and Medical Devices, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
  • 3.Institute of Regulatory Science for Medical Products, Tsinghua University, Beijing 100084, China
  • 4.Peking Union Medical College Hospital, Beijing 100032, China
  • 5.Shouyao Holdings Co., Ltd., Beijing 100176, China
Published: 2026-06-17 doi: 10.13699/j.cnki.1001-6821.2026.11.021
Outline
收藏切换

Clinical pharmacology research is a crucial component in the evaluation of new drugs, as it effectively reveals the drug’s metabolic processes, mechanisms of action and safety profile. The conditional approval policy typically accelerates the approval process based on limited clinical evidence, which often results in more simplified pre-marketing clinical pharmacology studies, shorter development timelines and smaller sample sizes. Oncology is the therapeutic area with the highest number of conditionally approved drugs, balancing the pre-marketing and post-marketing clinical pharmacology studies requires attention. This paper provides a comparative analysis of the pre-marketing and post-marketing clinical pharmacology studies for conditionally approved oncology drugs by the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA), highlighting the research patterns for different drug types. The study finds that the FDA generally requires more comprehensive clinical pharmacology studies, particularly in special populations (such as patients with impaired liver or kidney function and pediatric populations) and drug interaction studies, while the NMPA’s requirements are relatively simplified. This paper aims to provide insights for the development of oncology drugs in China and discusses the implementation and requirements of clinical pharmacology studies in the development of new drugs under conditional approval.

clinical pharmacology  /  oncology drugs  /  conditional approval  /  accelerated approval  /  National Medical Products Administration  /  U.S. Food and Drug Administration
Jing AN, Cheng-hao GE, Yang LIU, Sen LIU, Chen YIN, Yi LI, Jing-can WANG, Xiao-yuan CHEN. Analysis of pre-marketing and post-marketing clinical pharmacology studies in conditional approvals for oncology drugs in China and the United States[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (11) : 1631 -1639 . DOI: 10.13699/j.cnki.1001-6821.2026.11.021
Appendix
Less
Year 2026 volume 42 Issue 11
PDF
252
53
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.11.021
  • Receive Date：2026-04-01
  • Online Date：2026-08-06
  • Published：2026-06-17
Article Data
Affiliations
History
  • Received：2026-04-01
Affiliations
    1.R&G PharmaStudies Co., Ltd, Beijing 100048, China
    2.Clinical Trial Center for Drugs and Medical Devices, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
    3.Institute of Regulatory Science for Medical Products, Tsinghua University, Beijing 100084, China
    4.Peking Union Medical College Hospital, Beijing 100032, China
    5.Shouyao Holdings Co., Ltd., Beijing 100176, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.11.021
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House